SGRY — Surgery Partners, Inc.

Surgery Partners (SGRY) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $821.5 million, up 6.6% year-over-year.
• Adjusted EBITDA: $136.4 million, a 6.1% increase, with an adjusted EBITDA margin of 16.6%.
• Same Facility Revenue Growth: Increased by 6.3%.
• Surgical Cases: Over 166,000 performed, representing 2.1% growth.
• Cash Balance: $203.4 million with total liquidity exceeding $600 million.
• Debt: Approximately $2.2 billion in corporate debt; net leverage ratio at 4.2 times.

2. Strategic Updates and Business Highlights

• Organic Growth: Continued strong performance in GI and MSK procedures, particularly in orthopedics, with total joint surgeries growing 16% in Q3.
• Capital Deployment: $71 million spent on acquisitions in 2025; divested three ASCs for $50 million.
• De Novo Facilities: Two new facilities opened, with nine under construction and over a dozen in the development pipeline, primarily focusing on higher acuity specialties.
• Portfolio Optimization: Ongoing review aimed at divesting larger surgical hospitals to enhance cash flow and reduce leverage.

3. Forward Guidance and Outlook

• Revised Full-Year Guidance: Expected revenue between $3.275 billion and $3.3 billion; adjusted EBITDA between $535 million and $540 million.
• Same Facility Revenue Growth: Now anticipated to align with the midpoint of the long-term target range of 4% to 6%.
• Q4 Expectations: Cautious outlook due to recent volume and payer mix trends, particularly among commercial patients.

4. Bad News, Challenges, or Points of Concern

• Volume Growth: Softer than expected same facility volume growth observed, prompting a revision in Q4 outlook.
• Payer Mix Shift: Notable increase in government payer mix (Medicare) at the expense of commercial payers, which could impact margins.
• De Novo Ramp-Up Delays: Recent openings have not reached breakeven as quickly as anticipated due to construction and regulatory delays.
• M&A Activity: Slower pace of acquisitions and capital deployment, with only $71 million spent against a target of $250 million for the year.

5. Notable Q&A Insights

• Volume Weakness: Management acknowledged broader-based weakness in procedure volumes, not isolated to specific specialties, and attributed it to macroeconomic factors.
• Acquisition Strategy: The company remains disciplined in its M&A approach, with a strong pipeline but cautious about timing.
• Payer Mix Dynamics: Management noted no systemic issues affecting payer mix but acknowledged a weaker trend entering Q4, which they are monitoring closely.
• De Novo Facilities: Continued focus on higher acuity specialties, with a strong pipeline despite some delays in construction and regulatory approvals.
• Portfolio Review: Active discussions on divesting certain assets to enhance cash flow and reduce leverage, with a focus on facilities that do not align with their core short-stay surgical model.

This summary encapsulates the key points from Surgery Partners' Q3 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.